BC Week In Review | Aug 4, 2014
Company News

Inform Genomics management update

Inform Genomics Inc. , Boston, Mass.   Business: Diagnostic   Hired: Carl de Moor as chief technology officer, formerly senior principal epidemiology and lead at the Epidemiology Center of Excellence at IMS Health Holdings Inc.  ...
BC Week In Review | Oct 21, 2013
Company News

Inform Genomics, Tesaro deal

Tesaro will use Inform Genomics' bioinformatics and genomic platforms to evaluate the risk of chemotherapy-induced nausea and vomiting (CINV) in patients who receive "certain" moderately emetogenic chemotherapy regimens and standard antiemetic therapy without a neurokinin...
BC Week In Review | Oct 8, 2012
Clinical News

OnPART diagnostic data

Top-line data from 384 patients with breast, colorectal, lung or ovarian cancer who were receiving a standard chemotherapy regimen in an initial study showed that OnPART met the primary endpoint with a sensitivity and specificity...
BioCentury | Aug 13, 2012
Emerging Company Profile

Inform Genomics: SNPing side effects

Inform Genomics Inc. is developing its OnPART test to predict which cancer patients are most likely to have chemotherapy side effects and allow doctors to treat the unwanted effects earlier or change the chemotherapy regimens...
BC Week In Review | Jul 16, 2012
Clinical News

OnPART: Preliminary data

Preliminary data from 30 patients with breast cancer receiving doxorubicin, cyclophosphamide and paclitaxel in an initial study showed that OnPART correctly identified patients at risk for chemotherapy-induced diarrhea with 96.7% accuracy. Data were presented at...
BC Week In Review | Dec 5, 2011
Financial News

Inform Genomics completes venture financing

Inform Genomics Inc. , Boston, U.K.   Business: Cancer, Inflammation   Date completed: 12/1/11   Type: Venture financing   Raised: $1 million   Investors: Angel investors; company management   Note: The company raised over $1 million...
Items per page:
1 - 6 of 6
BC Week In Review | Aug 4, 2014
Company News

Inform Genomics management update

Inform Genomics Inc. , Boston, Mass.   Business: Diagnostic   Hired: Carl de Moor as chief technology officer, formerly senior principal epidemiology and lead at the Epidemiology Center of Excellence at IMS Health Holdings Inc.  ...
BC Week In Review | Oct 21, 2013
Company News

Inform Genomics, Tesaro deal

Tesaro will use Inform Genomics' bioinformatics and genomic platforms to evaluate the risk of chemotherapy-induced nausea and vomiting (CINV) in patients who receive "certain" moderately emetogenic chemotherapy regimens and standard antiemetic therapy without a neurokinin...
BC Week In Review | Oct 8, 2012
Clinical News

OnPART diagnostic data

Top-line data from 384 patients with breast, colorectal, lung or ovarian cancer who were receiving a standard chemotherapy regimen in an initial study showed that OnPART met the primary endpoint with a sensitivity and specificity...
BioCentury | Aug 13, 2012
Emerging Company Profile

Inform Genomics: SNPing side effects

Inform Genomics Inc. is developing its OnPART test to predict which cancer patients are most likely to have chemotherapy side effects and allow doctors to treat the unwanted effects earlier or change the chemotherapy regimens...
BC Week In Review | Jul 16, 2012
Clinical News

OnPART: Preliminary data

Preliminary data from 30 patients with breast cancer receiving doxorubicin, cyclophosphamide and paclitaxel in an initial study showed that OnPART correctly identified patients at risk for chemotherapy-induced diarrhea with 96.7% accuracy. Data were presented at...
BC Week In Review | Dec 5, 2011
Financial News

Inform Genomics completes venture financing

Inform Genomics Inc. , Boston, U.K.   Business: Cancer, Inflammation   Date completed: 12/1/11   Type: Venture financing   Raised: $1 million   Investors: Angel investors; company management   Note: The company raised over $1 million...
Items per page:
1 - 6 of 6